Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Napabucasin + FOLFIRI vs Napabucasin in previously treated metastatic colorectal cancer
2024-518204-50-00Phase 3Authorised
- Sponsor
- 1Globe Health Institute
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of napabucasin in colorectal cancer (CRC) (2 arms), sponsored by 1Globe Health Institute. Primary endpoint: Overall survival (OS) in the general study population. Planned start Nov 2024; status: authorised.
02
Drugs
napabucasin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2024-518204-50-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518204-50-00.